IRulya Therapeutics Inc.
IRLA· Nasdaq
Filed Mar 16, 2020 · 10-K · 76 days after period end · 0001564590-20-011165
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|
| Net Income | -$12.38M | -$3.47M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Dec 31, 2019 · filed Mar 16, 2020 · 76 d after period end